Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Editorial
Should Deubiquitinating Enzymes be Targeted for Therapy?
| Sokol V Todi1* and Chittaranjan Das2 | |
| 1Department of Pharmacology and Department of Neurology, Wayne State University School of Medicine, USA | |
| 2Department of Chemistry, Purdue University, USA | |
| Corresponding Author : | Sokol V Todi Assistant Professor, Department of Pharmacology and Department of Neurology Wayne State University School of Medicine 540 E. Canfield, Scott Hall Rm 6105, Detroit Michigan 48201, USA Tel: +1(313)577-1173 E-mail: stodi@med.wayne.edu |
| Received August 16, 2012; Accepted August 17, 2012; Published August 23, 2012 | |
| Citation: Todi SV, Das C (2012) Should Deubiquitinating Enzymes be Targeted for Therapy? Clinic Pharmacol Biopharm. 1:e108. doi:10.4172/2167-065X.1000e108 | |
| Copyright: © 2012 Todi SV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Effective, non-toxic therapies for many diseases, including malignancies, metabolic syndromes and age-dependent neurodegeneration remain elusive, though not for lack of effort from scientists all over the world.
